These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 25185736)

  • 21. [Rifaximin in the treatment of hepatic encephalopathy].
    Lata J; Hůlek P; Fejfar T; Spicák J; Drastich P; Marecek Z; Brůha R; Husová L; Senkyrík M
    Vnitr Lek; 2002 Jun; 48(6):578-82. PubMed ID: 12132365
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug therapy: rifaximin.
    Bajaj JS; Riggio O
    Hepatology; 2010 Oct; 52(4):1484-8. PubMed ID: 20814894
    [No Abstract]   [Full Text] [Related]  

  • 23. Rifaximin is an efficacious treatment for the Parkinsonian phenotype of hepatic encephalopathy.
    Kok B; Foxton MR; Clough C; Shawcross DL
    Hepatology; 2013 Oct; 58(4):1516-7. PubMed ID: 23471844
    [No Abstract]   [Full Text] [Related]  

  • 24. [Hepatic encephalopathy. Rifaximin opens new perspectives].
    MMW Fortschr Med; 2014 Jul; 156(13):78-9. PubMed ID: 25318235
    [No Abstract]   [Full Text] [Related]  

  • 25. Rifaximin is largely safe and well tolerated but caution is necessary when taken with statins.
    Cacciottolo TM; Kingdon A; Alexander GJ
    Clin Gastroenterol Hepatol; 2014 Oct; 12(10):1765. PubMed ID: 24703862
    [No Abstract]   [Full Text] [Related]  

  • 26. Rifaximin for treatment of hepatic encephalopathy.
    Maclayton DO; Eaton-Maxwell A
    Ann Pharmacother; 2009 Jan; 43(1):77-84. PubMed ID: 19092143
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rifaximin: a nonsystemic antibiotic for hepatic encephalopathy.
    Welliver M
    Gastroenterol Nurs; 2013; 36(2):140-2. PubMed ID: 23549218
    [No Abstract]   [Full Text] [Related]  

  • 28. Rifaximin therapy and Clostridium difficile infection: a note of caution.
    Zullo A; Ridola L; Hassan C
    J Clin Gastroenterol; 2013 Sep; 47(8):737. PubMed ID: 23507769
    [No Abstract]   [Full Text] [Related]  

  • 29. Editorial: rifaximin and minimal hepatic encephalopathy.
    Butterworth RF
    Am J Gastroenterol; 2011 Feb; 106(2):317-8. PubMed ID: 21301455
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rifaximin for the treatment of hepatic encephalopathy.
    Mullen K; Prakash R
    Expert Rev Gastroenterol Hepatol; 2010 Dec; 4(6):665-77. PubMed ID: 21108586
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Covert Hepatic Encephalopathy: Who Should Be Tested and Treated?
    Flamm SL
    Clin Liver Dis; 2015 Aug; 19(3):473-85. PubMed ID: 26195202
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Prevention and treatment of hepatic encephalopathy].
    Sivolap YP
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(10):144-147. PubMed ID: 29171503
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of rifaximin use for hepatic encephalopathy on the risk of early post-transplant infections in liver transplant recipients.
    Sun HY; Wagener M; Cacciarelli TV; Singh N
    Clin Transplant; 2012; 26(6):849-52. PubMed ID: 22432742
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Uncommon Movement Disorders in Chronic Hepatic Disease with Response to Rifaximin.
    Sousa AL; Salgado P; Alves JE; Silva S; Ferreira S; Magalhães M
    Tremor Other Hyperkinet Mov (N Y); 2019; 9():. PubMed ID: 31413898
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is Lactulose Plus Rifaximin Better than Lactulose Alone in the Management of Hepatic Encephalopathy?
    Butt NI; Butt UI; Kakar AATK; Malik T; Siddiqui AM
    J Coll Physicians Surg Pak; 2018 Feb; 28(2):115-117. PubMed ID: 29394969
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
    Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P
    Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Review article: potential mechanisms of action of rifaximin in the management of hepatic encephalopathy and other complications of cirrhosis.
    Bajaj JS
    Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():11-26. PubMed ID: 26618922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A non-absorbable rifamycin for treatment of hepatic encephalopathy.
    Testa R; Eftimiadi C; Sukkar GS; De Leo C; Rovida S; Schito GC; Celle G
    Drugs Exp Clin Res; 1985; 11(6):387-92. PubMed ID: 3836135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study.
    Sanyal A; Younossi ZM; Bass NM; Mullen KD; Poordad F; Brown RS; Vemuru RP; Mazen Jamal M; Huang S; Merchant K; Bortey E; Forbes WP
    Aliment Pharmacol Ther; 2011 Oct; 34(8):853-61. PubMed ID: 21848797
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of Rifaximin in prevention of recurrence of hepatic encephalopathy in patients with cirrhosis of liver.
    Ali B; Zaidi YA; Alam A; Anjum HS
    J Coll Physicians Surg Pak; 2014 Apr; 24(4):269-73. PubMed ID: 24709242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.